NCT07235410

Brief Summary

Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment. However, patients often respond differently to TACE, and it is difficult to predict who will benefit most. This study uses deep learning to automatically analyze routine CT images taken before TACE. By measuring body composition features, such as the size and condition of different abdominal organs and tissues, we aim to better understand patients' overall health status and treatment tolerance. The goal is to develop a prediction model that can help doctors estimate survival and treatment outcomes more accurately. This may assist in making more personalized treatment decisions and improving patient care.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
6mo left

Started Nov 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress51%
Nov 2025Nov 2026

Study Start

First participant enrolled

November 1, 2025

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

November 14, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 19, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Expected
Last Updated

November 19, 2025

Status Verified

November 1, 2025

Enrollment Period

2 months

First QC Date

November 14, 2025

Last Update Submit

November 14, 2025

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

  • OS

    After the TACE procedure until May 1, 2025

Secondary Outcomes (1)

  • PFS

    After the TACE procedure until May 1, 2025

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

hepatocellular carcinoma

You may qualify if:

  • Patients diagnosed with "Hepatocellular Carcinoma" from January 1, 2018 to May 31, 2024;
  • Age \> 18 years old.

You may not qualify if:

  • Poor image quality;
  • Loss of follow-up;
  • Presence of another type of malignant tumor other than liver cancer;
  • Incomplete medical records.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Central Study Contacts

Yuanyuan Chu

CONTACT

+8602785726375whunionlunli@126.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Archiater

Study Record Dates

First Submitted

November 14, 2025

First Posted

November 19, 2025

Study Start

November 1, 2025

Primary Completion

December 31, 2025

Study Completion (Estimated)

November 1, 2026

Last Updated

November 19, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)